Kornimate/medical-research-clean huggingface dataset:
omega-3 fatty acid supplementation to enhance performance

Conditions: Strength; Body Composition; Muscle Soreness

Summary: the goal of this intervention study is to determine if omega-3 fatty acid supplementation as compared to placebo improves performance in track and field athletes. the main questions it aims to answer are: 1. can performance be improved 2. can strength be enhanced 3. will positive body composition changes occur (lean vs fat mass) 4. will feelings of muscle soreness be diminished participants will take either omega-3 fatty acid supplements or placebo and continue with their sport specific training regimen. researchers will compare the supplement group to placebo group to determine if there are any significant differences.

this is a randomized, placebo-controlled trial to determine the efficacy of fish oil-derived omega-3 fatty acid supplementation. up to sixty participants will be randomized to receive one of two conditions: 4.0 grams of fo n-3/day or placebo (coconut oil) for the 10-week protocol study period. nordic naturals (ultimate omega) will be used as the intervention at a dose of 6 capsules/day (3840 mg total fo/1950 mg epa/1350 mg dha). although protocols have varied among studies with regards to dosage, the proposed regimen was selected based on studies on strength in older adults and college-aged athletes utilizing a range of 2-5g fo n-3 per day. blinded randomization will be accomplished with a research associate providing every first (of two) participants the placebo, while the second will receive the supplemented condition until recruitment is complete. participants will be provided their supplement in 2-week increments and instructed to consume with/near their evening meal. used bottles will be returned after two weeks and participants will receive the next 2-week supply of supplement and the leftover pill count will determine compliance rate. the target population is apparently healthy college athletes (male and female of all ethnicities) between the ages of 18-25 years at baylor university. participants must be able to read and understand english and sign their own consent form. up to 60 subjects will be recruited via direct contact or team briefings with permission of the coaches.

Eligibility criteria:
inclusion criteria: apparently healthy college athletes (male and female of all ethnicities) between the ages of 18-25 years. exclusion criteria: -participants will be excluded if they are unable to physically train due to injury/illness or are pregnant, or have a known heart condition or pacemaker.

Keywords: omega-3 fatty acid strength body composition muscle soreness
the women's screening and self-testing program (prometa) study

Conditions: Human Papilloma Virus Related Cervical Carcinoma

Summary: this proposal directly addresses the ability to safely scale-up a screen-triage-treat approach to cervical cancer screening. the investigators propose to capitalize on a pool of screen-eligible women accessing routine care within targeted human immunodeficiency virus (hiv) care and treatment services. the primary outcome of interest is the number of women screened and the proportion of screen-positive women undergoing treatment. secondary outcomes will focus on other implementation outcomes, and if successful, will be utilized to inform future research to take this approach to scale across mozambique.

this study will use a hybrid type iii effectiveness-implementation design. in a hybrid type iii design, the primary focus is on testing of an implementation strategy, while simultaneously continuing to observe and gather information on the effectiveness of a clinical intervention, under real world conditions, for which effectiveness data has already largely been determined. best practices for deploying the screen-triage-treat approach to cervical cancer screening utilizing self-collected human papilloma virus (hpv) deoxyribonucleic acid (dna) testing within mozambique´s hiv care and treatment services will be evaluated. the study will employ a mixed-methods approach, collecting both quantitative and qualitative data. the primary outcome of interest is the number of women screened and the proportion of hpv screen-positive women undergoing treatment, while secondary outcomes will focus on other implementation outcomes, and if successful, will be utilized to inform future research to take this approach to scale across mozambique.

Eligibility criteria:
inclusion criteria: * women 25-49 years * accessing hiv care and treatment services * not being pregnant * patients with a cervix exclusion criteria: * physical or mental impairment that inhibits participation in the study * pregnant women or \<6 weeks post-partum * women who have undergone a total hysterectomy with removal of the cervix

Keywords: human immunodeficiency virus self swab mozambique cervical cancer implementation science
erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer (nsclc) and eastern cooperative oncology group (ecog)performance status (ps) 2

Conditions: Non-Small Cell Lung Cancer

Summary: the purpose of this noncomparative study is to obtain preliminary estimates of the efficacy of erlotinib and standard chemotherapy in patients with advanced, previously untreated nonsmall cell lung cancer (nsclc) and an eastern cooperative oncology group (ecog) performance status (ps) of 2. the study will also evaluate the safety of single-agent erlotinib in this patient population.


Eligibility criteria:
inclusion criteria: * stage iiib or iv nonsmall cell lung cancer (nsclc) * no prior chemotherapy * eastern cooperative oncology group (ecog) performance status 2 * clinically or radiologically measurable disease per recist criteria exclusion criteria: * gastro-intestinal abnormalities * any concurrent anticancer therapy * prior treatment with epidermal growth factor receptor (egfr) inhibitors of any kind * other active malignancies * uncontrolled brain metastases * severe abnormalities of the cornea * significant cardiac disease

Keywords: tarceva nsclc egfr ecog performance status 2 erlotinib non-small cell lung cancer osi-774
rtms for refractory auditory hallucinations based on personalized targets using magnetoencephalography

Conditions: Refractory Auditory Hallucinations; Schizophrenia

Summary: this study is an before-after study in the same patient, which enrolled 36 psychiatric patients with refractory auditory hallucinations. the target of patient intervention relies on the results of magnetoencephalography localization. the medication and dosage remain unchanged during the intervention period. the investigators assume that the intervention targets for each auditory hallucination patient are individualized.

this study is divided into two parts: 1. target determination. firstly, meg data of the patient's resting and task states are collected, and a precise localization model using magnetoencephalography is applied to locate the precise location of the patient's abnormal signals in the brain, which is then used as the intervention target. based on the patient's tolerance for single day intervention, the appropriate number of targets is generally 2-4. the upper limit of targets is 4. 2. rtms individualized intervention. application of rtms for 1hz low-frequency intervention, with intervention parameters of 1400 sessions, 100% exercise threshold, and a total of 23 minutes per session. after each target intervention, rest for half an hour to one hour. the pseudo stimulation intervention lasted for 10 days in the first and second weeks, and the scale was evaluated after the end of the pseudo stimulation. after resting for 2 weeks, enter the 3-4 weeks of real stimulation, with 5 days of intervention per week for a total of 10 days. 2-4 targets per day, 23 minutes per target, with 30-60 minutes between interventions for each target. after the fourth week, evaluate the scale. follow up evaluations will be conducted on the 7th, 14th, 30th, 60th, and 90th day after intervention. by analyzing and evaluating data, explore individualized treatment plans for auditory hallucinations in clinical practice.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of schizophrenia * must be able to right-handed * primary school education or above * understand and sign a written informed consent form (jointly signed by the guardian and the participant if under 18 years old) * existence of persistent auditory hallucinations (defined as: taking sufficient antipsychotic medication for at least 6 months, combined with 3 antipsychotic medications still ineffective, and no significant improvement in auditory hallucinations symptoms, with an ahrs score still\>12) exclusion criteria: * mect treatment within the past 3 months * major physical illnesses (organic lesions such as sensory and motor disorders, neurological disorders, and traumatic brain injury) * taboo symptoms for rtms treatment (such as intracranial metal implants) * aggressive behavior and an impulse to damage equipment * metal (including orthodontic treatment, dental implants) and tattoos inside the body * claustrophobia

Keywords: auditory hallucinations rtms meg individualized targets
the effect of intensive insulin therapy

Conditions: the Maintenance of Normoglycemia; the Incidence of Ventilator Associated Pneumonia (VAP); Treatment Period in the Intensive Care Unit

Summary: aim. to determine whether the maintenance of normoglycemia decreases the incidence of ventilator associated pneumonia (vap), reduces its treatment period and the length of stay in the intensive care unit. methods. prospective, randomized, controlled trial. we enrolled 117 mechanically ventilated trauma (71) and abdominal (46) surgical patients, older than 18, of both sex. in 57 patients (strict glucose control group) we aimed to maintain the blood glucose level between 4.4 and 6. 1 mmol/l, while in 60 patients (standard glucose control group) it was maintained between 7.8 and 10.0 mmol/l, with the use of continues insulin infusion. insulin dose adjustments were based on measurements of glucose in capillary blood sample. key words: surgical patients; mechanical ventilation; pneumonia; blood glucose; insulin infusion; hospital stay

see brief summary

Eligibility criteria:
inclusion criteria: * surgical patients * mechanical ventilated * both sex * older than 18 exclusion criteria: * non-surgical patients * non mechanical ventilated * younger than 18 * pregnant women

Keywords: mechanical ventilated surgical patients pneumonia blood glucose insulin infusion hospital stay
treatment of monosymptomatic nocturnal enuresis

Conditions: Nocturnal Enuresis

Summary: a prospective randomized trial to study the effect of spinal magnetic stimulation versus posterior tibial neuromodulation in the treatment of monosymptomatic nocturnal enuresis.

nocturnal enuresis is defined as "nighttime bedwetting in children aged five years or older.currently available treatment options for nocturnal enuresis include medication, wetting alarms, lifestyle changes, sacral magnetic stimulation, and posterior tibial neurmodulation. magnetic stimulation is a valid method for stimulation of sacral as functional electrical stimulation. it generates a more powerful and deeper electrical field than that produced by conventional electrical stimulators. so, magnetic stimulation could be considered an attractive form of electrical therapy, being relatively painless, non-invasive and free from side effects.peripheral neuromodulation is the modulation of the physiologic behavior of the nerve by electrical stimulation. posterior tibial neuromodulation is an effective method in treatment of urinary incontinence

Eligibility criteria:
inclusion criteria: * all subjects were diagnosed as patients with mne according to the diagnostic and statistical manual of mental disorders, 4th revised edition (dsm-iv) (american psychiatric association's dsm-iv, 1994): bed-wetting ≥3 times a week; lasting more than 6 months; can control urination during the day but cannot control urination after falling asleep. exclusion criteria: * - patients younger than 5 years old. * patients who have any abnormality in blood or urine biochemistry. * patients with other urinary symptoms. * patients with neurological or endocrinal abnormalities (such as cerebral palsy, spinal cord lesion, peripheral neuropathy or diabetes mellitus)

Keywords: spinal magnetic stimulation, nocturnal enuresis, neuromodulation
post mastectomy shoulder problems and kinesio taping

Conditions: Post Mastectomy Complications

Summary: applications of new treatment modality which is kinesio tape in post mastectomy shoulder problems.

post-mastectomy complications are often noted and complaints by breast cancer survivors. it often involves the development of chronic arm pain with accompanying limitation of shoulder motion. aim of the study was to investigate the effect of the kinesio tape (kt) on the shoulder pain and range of motion (rom). method: 74 female patients underwent modified radical mastectomy were involved in this study. they were randomly divided into two groups, experimental who received kt for shoulder joint in addition to conventional physiotherapy program while, the control group received the physiotherapy program only. outcome measures were visual analogues scale, shoulder rom and shoulder pain and disability index.

Eligibility criteria:
inclusion criteria: * underwent modified radical mastectomy for at least 2 weeks and taking chemotherapy and radiation therapy for stage 1 or ii breast cancer. * presence of shoulder pain with associated limitation of motion of the shoulder. * good compliance and willingness to participate in kinesio taping sessions with a written consent exclusion criteria: * still diagnosed with active breast ca at the time of the study. * presence of skin hypersensitivity to kinesio tape material. * presence of treatment contraindications including the presence of a pacemaker, heart disease, pregnancy, infectious disease, epilepsy thrombophlebitis, arterial hypertension or metastatic cancer . * presence of mental disturbances of the sensorium or language problems which can make communication and cooperation problematic.

Keywords: mastectomy shoulder pain rom kinesio tape
self-management and health promotion in early-stage dementia with e-learning for carers

Conditions: Dementia

Summary: this study aims to assess if an educational programme combining approaches of self-management, health promotion, and e-learning will improve self-efficacy and other key health and mental health outcomes for people with mild to moderate dementia.

it is currently estimated that 47 million people are living with dementia today and this number is expected to double in the next 20 years. unfortunately, there has been limited advancement in medical treatments for dementia and new cost-effective approaches are needed. the utility of self-management has been proven to be of benefit in certain chronic diseases, however, very little work has been undertaken regarding self-management in people with dementia.the shape self-management group therapy aims to significantly improve self-efficacy in people with mild to moderate dementia and to improve key health and mental health outcomes, carer stress and knowledge of dementia.shape comprises a 10 week online course delivered as group sessions for the participants with dementia. the sessions are designed to develop self-management skills and to provide information on the disease process and the development of healthy behaviours in a supportive learning environment to prevent problems that are common in the later stages of the disease. e-learning resources will be provided for carers (study supporters) which covers the similar and complimentary material discussed in the group sessions for the participant with dementia. this trial uses 2:1 randomisation and will assess the clinical and cost effectiveness of shape. participants will be randomised to participate in the shape intervention or continue with usual care. to assess the effectiveness of shape at improving self-efficacy and secondary outcomes a battery of questionnaires will be administered to the participants and study supporters at baseline, after shape participants have completed the intervention, and 9 months after randomisation. the answers to these questionnaires will be assessed and the results compared between the two groups of participants.

Eligibility criteria:
inclusion criteria: * diagnosis of dementia according to the icd-10 classification or the diagnostic and statistical manual of mental disorders (dsm) iv or v * 65 years of age or older * mild to moderate dementia, as associated with tmmse ≥15 * ability to read and write * hearing and vision that are sufficiently good to work in a group setting * capacity to give consent for participation in the study * proficient in the language in which the intervention is provided * care partner willing to participate exclusion criteria: * a diagnosis of alcohol or drug abuse * lewy body dementias, fronto-temporal lobar degeneration or semantic dementia * a limited life expectancy due to any terminal disease or other serious illness, other than dementia * chemotherapy or radiation treatment ongoing at enrolment * currently participating in health promotion or self-management group

Keywords: health promotion self-management online
melatonin as adjuvant treatment for adhd in adults

Conditions: Attention Deficit Hyperactivity Disorder

Summary: this study aims to evaluate the effect of melatonin supplementation as adjuvant treatment in adhd in adults.


Eligibility criteria:
inclusion criteria: male and female age 18-60 inclusive. primary diagnosis of adhd aisrs total score ≥ 24 cgi-s ≥4 (moderately ill or worse). understands and is able, willing, and likely to fully comply with the study procedures and restrictions. has given written informed consent to participate in the study. exclusion criteria: bmi less than18.5 or greater than 35. any underlying/ history or current diagnosis of systemic and/or metabolic disease (e.g. diabetes, crohn's disease) and/or neurological condition state that may render the subject illegible to participate in the study as assessed by medical history, physical exam, clinical and lab evaluation. history of uncontrolled hypertension or a resting systolic blood pressure \> 140mmhg or diastolic blood pressure \> 90mmhg (subjects with well controlled hypertension on a stable dose (2 months) of anti-hypertensives will be allowed to participate). major depression or anxiety disorder which is a focus of treatment or requires taking medication. a lifetime history of psychosis or bipolar disorder has any concurrent chronic or unstable medical condition that could confound with the results of safety assessments, increase risk to the subject or lead to difficulty complying with the protocol. subjects taking any medication with cns effects subjects with a history of two or more prior failed adequate trials of adhd treatment due to adverse events. use of dietary supplements with potential cns effect, including omega-3 supplements, 30 days before study initiation and throughout the study. clinical history of cognitive impairment in judgment of investigator. pregnant or breast-feeding subjects. women of childbearing potential must have a negative pregnancy test performed at screening visit prior to randomization. women of childbearing potential must agree to use adequate birth control for the entire duration of the study. subjects with a current (within the last 3 months) dsm-v diagnosis of alcohol or drug abuse or dependence (excluding nicotine). has taken an investigational drug or taken part in a clinical trial within 30 days prior to screening. any other reason that, in the opinion of the investigator, prevents the subject from participating in the study or compromise the subject safety. previous use of melatonin or melatonin analogues
ctc in predicting neoadjuvant chemotherapy among labc patients: a single-center, prospective, exploratory clinical trial

Conditions: Locally Advanced Breast Cancer; Circulating Tumor Cell

Summary: the gilupi cellcollector® is the first in vivo ctc isolation product worldwide, which is ce approved. the purpose of this clinical trial is to evaluate the predictive value of ctc in neoadjuvant chemotherapy among locally advanced breast cancer patients.


Eligibility criteria:
inclusion criteria: * patients with histologically confirmed primary invasive breast adenocarcinoma, anatomic stage t2-4n0-3m0 or t1n1-3m0 before neoadjuvant chemotherapy * ecog 0-1 * adequate organ function * consent to undergo ctc analysis in vivo exclusion criteria: * pregnant or breastfeeding patients * metastatic or recurrent patients * uncontrollable infection
chondroitin sulphate treatment efficacy in rhizarthrosis.

Conditions: Rhizarthrosis

Summary: patients who present rhizarthrosis diagnostic will be randomized to be treated with chondroitin sulfate or placebo during 24 weeks to study the effect of the treatment with objective and subjective indicators of pain and sensibility.


Eligibility criteria:
inclusion criteria: * both sex patients * age between 45 to 75 years * with mechanical pain at the trapezium-thumb metacarpal joint of more than 3 months duration * grade ii or iii eaton \& glickel rhizarthrosis radiological diagnose * pain at inclusion of \>= 40 mm at a visual analogue scale * without rehabilitation treatment or infiltration in the last 6 months * who accept to participate and sign informed consent exclusion criteria: * patients with rhizarthrosis resulted from rheumatic disease * patients with joint surgery or traumatic background * illiterate patients or unable to understand informed consent * patients with previous neuropsychopathology enough severe to unable participation at the study * patients with peripheral sensory impairment due to diabetes, peripheral neuropathy or central neurological sequelae of disease in the affected limb that can alter sensory perception * patients with coagulopathy * inflammation for other process at the joint at study * in treatment with non-steroidal anti-inflammatory drug in the last 7 days and/or corticosteroid in the last 30 days * allergy or hypersensibility at chondroitin sulfate or its excipients * pregnant or breastfeeding woman

Keywords: rhizarthrosis chondroitin sulfate placebo